Skip to main content

Advertisement

Log in

Intravenous Sotalol for the Treatment of Ventricular Dysrhythmias in an Infant on Extracorporeal Membrane Oxygenation

  • Case Report
  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

Abstract

Sotalol is a class III anti-arrhythmic agent with beta receptor blocking properties. Intravenous (IV) sotalol may be useful to treat refractory atrial and ventricular arrhythmias. A report on the efficacy and safety of IV sotalol in an infant on extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT), who developed refractory ventricular arrhythmias following surgery for congenital heart disease. A 10-day old infant with severe pulmonary valve stenosis underwent surgical pulmonary valvectomy and enlargement of the main pulmonary artery. Post-operatively, the patient developed hemodynamically significant accelerated idioventricular rhythm which was not responsive to a combination of amiodarone, lidocaine, and procainamide leading to 2 cardiac arrest events and placement on ECMO. The amiodarone infusion was uptitrated to 20 mcg/kg/min, but episodes of the hemodynamically compromising arrhythmia continued. Amiodarone was discontinued and IV sotalol was initiated at 42 mg/m2/day, divided to 3 doses, and administered every 8 h, which completely suppressed the arrhythmia. The initial sotalol dose was calculated based on a daily dose of 90 mg/m2 and reduced by an age-related factor as recommended by the FDA approved prescribing information. Subsequently, acute kidney injury requiring CRRT developed. The patient remained on IV sotalol for 3 weeks and then transitioned to oral sotalol. The oral dose was increased to 44 mg/m2/day (3.5 mg every 8 h) to account for the difference in bioavailability between the IV and oral formulations. Serial sotalol levels during IV and PO therapy remained therapeutic on ECMO and CRRT. The patient maintained normal sinus rhythm on sotalol without adverse events. IV sotalol in the setting of ECMO and CRRT was safe and effective in controlling refractory hemodynamically compromising accelerated idioventricular rhythm unresponsive to amiodarone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

References

  1. Shekar K, Fraser JF, Smith MT, Roberts JA (2012) Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care 27:741.e9–818.e9

    Article  CAS  Google Scholar 

  2. Milsap RL, Jusko WJ (1994) Pharmacokinetics in the infant. Environ Health Perspect 102:107–110

    Article  Google Scholar 

  3. Sotalol hydrochloride injection for intravenous use [package insert] (1992) Academic Pharmaceuticals, Lake Bluff

  4. Altathera Pharmaceuticals (2019) Dosing for pediatric patients under 2 years of age. https://www.altathera.com/dosing-calculator/. Accessed 12 May 2019

  5. Taketomo CK, Hodding JH, Kraus DM (2017) Pediatric & neonatal dosage handbook, 24th edn. Lexi-comp, Inc., Hudson

    Google Scholar 

  6. Valdes SO, Landstrom AP, Schneider AE et al (2018) Intravenous sotalol for the management of postoperative junctional ectopic tachycardia. Heart Rhythm Case Rep 4:375–377

    Google Scholar 

  7. Kim H, Wolff J, Dalal A, Van Hare GF, Avari Silva JN (2017) Use of intravenous sotalol in newborns with supraventricular tachycardia. Heart Rhythm Case Rep 3:332–335

    Google Scholar 

  8. Aljohani OA, Perry JC, Williams MR (2018) Intravenous sotalol for conversion of atrial flutter in infants. Heart Rhythm Case Rep 4:117–120

    Google Scholar 

  9. Li X, Zhang Y, Liu H, Jiang H, Ge H, Zhang Y (2017) Efficacy of intravenous sotalol for treatment of incessant tachyarrhythmias in children. Am J Cardiol 119:1366–1370

    Article  CAS  Google Scholar 

  10. Kannan R, Yabek SM, Garson A, Garson A Jr, Miller S, McVey P, Singh BN (1987) Amiodarone efficacy in a young population: relationship to serum amiodarone and desethylamiodarone levels. Am Heart J 114:283–287

    Article  CAS  Google Scholar 

  11. Kendrick JG, Macready JJ, Kissoon N (2006) Amiodarone treatment of junctional ectopic tachycardia in a neonate receiving extracorporeal membrane oxygenation. Ann Pharmacother 40:1872–1875

    Article  CAS  Google Scholar 

  12. Watt K, Li J, Benjamin D, Cohn-Wolkowiez M (2011) Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation. J Cardiovasc Pharmacol 58:126–132

    Article  CAS  Google Scholar 

  13. Allegaert K, van den Anker JN, Naulaers G, de Hoon J (2007) Determinants of drug metabolism in early neonatal life. Curr Clin Pharmacol 2:223–229

    Article  Google Scholar 

  14. Laer S, Elshoff JP, Meibohm B et al (2005) Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol 46:1322–1330

    Article  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hoang H. Nguyen.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jacobson, J.L., Somberg, J.C. & Nguyen, H.H. Intravenous Sotalol for the Treatment of Ventricular Dysrhythmias in an Infant on Extracorporeal Membrane Oxygenation. Pediatr Cardiol 41, 418–422 (2020). https://doi.org/10.1007/s00246-019-02225-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-019-02225-w

Keywords

Navigation